CL2009000896A1 - Compuestos derivados de 3-fenilpirazolo[5,1-b]tiazol sustituido; composicion farmaceutica; utiles en el tratamiento de la depresion, ansiedad, isquemia, apoplejia, hipertension, esquizofrenia, entre otras enfermedades. - Google Patents

Compuestos derivados de 3-fenilpirazolo[5,1-b]tiazol sustituido; composicion farmaceutica; utiles en el tratamiento de la depresion, ansiedad, isquemia, apoplejia, hipertension, esquizofrenia, entre otras enfermedades.

Info

Publication number
CL2009000896A1
CL2009000896A1 CL2009000896A CL2009000896A CL2009000896A1 CL 2009000896 A1 CL2009000896 A1 CL 2009000896A1 CL 2009000896 A CL2009000896 A CL 2009000896A CL 2009000896 A CL2009000896 A CL 2009000896A CL 2009000896 A1 CL2009000896 A1 CL 2009000896A1
Authority
CL
Chile
Prior art keywords
anxiety
depression
treatment
schizophrenia
hypertension
Prior art date
Application number
CL2009000896A
Other languages
English (en)
Inventor
Hisashi Shibata
Kodo Shikata
Akira Inomata
Kogyoku Shin
Taro Terauchi
Yoshinori Takahashi
M Hashizume
K Takeda
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of CL2009000896A1 publication Critical patent/CL2009000896A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

COMPUESTO DE FÓRMULA (1) O SALES DEL MISMO,. QUE EXHIBE EXCELENTE ANTAGONISMO DEL<br /> RECEPTOR CRF Y SUFICIENTE ACTIVIDAD FARMACOLÓGICA, SEGURIDAD Y PROPIEDADES FARMACOCINÉTICAS COMO<br /> UN FÁRMACO, DONDE R1, R2, R3, R4, 11 Y A12, SON COMO SE DEFINE EN LAS REIVINDICACIONES.<br /> COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE DICHO COMPUESTO O UNA SAL DEL MISMO COMO<br /> INGREDIENTE ACTIVO.<br /> USO DE DICHO COMPUESTO O UNA SAL DEL MISMO PARA EL TRATAMIENTO DE LA DEPRESIÓN, ANSIEDAD,<br /> ISQUÉMICA, APOPLEJÍA, HIPERTENSIÓN, ESQUIZOFRENIA, ENTRE OTRAS ENFERMEDADES.<br /> USO DE DICHO COMPUESTO O UNA SAL DEL MISMO PARA EL TRATAMIENTO O LA PREVENCIÓN DE LA DEPRESIÓN, SÍNTOMAS DEPRESIVOS, ANSIEDAD O SÍNDROME DEL INTESTINO IRRITABLE.<br />  
CL2009000896A 2008-04-15 2009-04-14 Compuestos derivados de 3-fenilpirazolo[5,1-b]tiazol sustituido; composicion farmaceutica; utiles en el tratamiento de la depresion, ansiedad, isquemia, apoplejia, hipertension, esquizofrenia, entre otras enfermedades. CL2009000896A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008106080 2008-04-15

Publications (1)

Publication Number Publication Date
CL2009000896A1 true CL2009000896A1 (es) 2010-04-16

Family

ID=41164535

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009000896A CL2009000896A1 (es) 2008-04-15 2009-04-14 Compuestos derivados de 3-fenilpirazolo[5,1-b]tiazol sustituido; composicion farmaceutica; utiles en el tratamiento de la depresion, ansiedad, isquemia, apoplejia, hipertension, esquizofrenia, entre otras enfermedades.

Country Status (29)

Country Link
US (1) US8431603B2 (es)
EP (1) EP2266990B1 (es)
JP (1) JP4654325B2 (es)
KR (1) KR101601994B1 (es)
CN (1) CN102007133B (es)
AR (1) AR071655A1 (es)
AU (1) AU2009237050B2 (es)
BR (1) BRPI0911659B8 (es)
CA (1) CA2721670C (es)
CL (1) CL2009000896A1 (es)
CY (1) CY1113484T1 (es)
DK (1) DK2266990T3 (es)
ES (1) ES2396126T3 (es)
HK (2) HK1150310A1 (es)
HR (1) HRP20121021T1 (es)
IL (1) IL208393A (es)
MX (1) MX2010011089A (es)
MY (1) MY152687A (es)
NZ (1) NZ588376A (es)
PE (1) PE20091890A1 (es)
PL (1) PL2266990T3 (es)
PT (1) PT2266990E (es)
RS (1) RS52561B (es)
RU (1) RU2482120C2 (es)
SI (1) SI2266990T1 (es)
TW (1) TW201004964A (es)
UA (1) UA101836C2 (es)
WO (1) WO2009128383A1 (es)
ZA (1) ZA201006764B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY152687A (en) 2008-04-15 2014-10-31 Eisai R&D Man Co Ltd 3-phenylpyrazolo[5,1-b]thiazole compound
WO2011043387A1 (ja) 2009-10-08 2011-04-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾロオキサゾール化合物
AR078521A1 (es) 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol
CN102020587A (zh) * 2010-11-25 2011-04-20 大连凯飞精细化工有限公司 2-甲氧基-4-氰基苯甲醛的合成方法
TWI679205B (zh) * 2014-09-02 2019-12-11 日商日本新藥股份有限公司 吡唑并噻唑化合物及醫藥
CN115010621B (zh) * 2022-07-21 2023-11-03 山东百启生物医药有限公司 一种4-溴-3-甲基苯甲腈的合成方法

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US224974A (en) 1880-02-24 wheeler
JPS5320360B2 (es) 1973-05-30 1978-06-26
JPS51141896A (en) * 1975-05-31 1976-12-07 Sankyo Co Ltd Process for preparing fused ring triazoropyrimidine derivatives
DE3269604D1 (en) 1981-06-26 1986-04-10 Schering Corp Novel imidazo(1,2-a)pyridines and pyrazines, processes for their preparation and pharmaceutical compositions containing them
US4596872A (en) * 1985-06-05 1986-06-24 Schering A.G. Imidazo[1,2-a]pyridines, and process for their preparation
FR2594438B1 (fr) * 1986-02-14 1990-01-26 Labaz Sanofi Nv Derives d'indolizine, leur procede de preparation ainsi que les compositions en contenant
US5190862A (en) * 1987-04-01 1993-03-02 Boehringer Mannheim Gmbh Chromogenic compounds and the use thereof as enzyme substrates
US5179103A (en) * 1987-06-15 1993-01-12 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutically useful pyrazolopyridines
US4925849A (en) * 1987-06-15 1990-05-15 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutically useful pyrazolopyridines
FR2619818B1 (fr) * 1987-09-01 1990-01-12 Sanofi Sa Imidazo (1,2-b) pyridazines, procede pour leur preparation et compositions pharmaceutiques les contenant
US5155114A (en) * 1989-01-23 1992-10-13 Fujisawa Pharmaceutical Company, Ltd. Method of treatment using pyrazolopyridine compound
US5338743A (en) * 1988-06-06 1994-08-16 Fujisawa Pharmaceutical Co., Ltd. New use of the adenosine antagonist
JPH0276880A (ja) 1988-06-16 1990-03-16 Sankyo Co Ltd 悪液質改善治療剤
KR900701787A (ko) 1988-07-19 1990-12-04 제임스 제이. 플린 치환된 페닐트리아졸로피리미딘 제초제
US5127936A (en) * 1988-07-19 1992-07-07 E. I. Du Pont De Nemours And Company Substituted phenyltriazolopyrimidine herbicides
CA1330079C (en) 1988-10-13 1994-06-07 Michihiko Tsujitani Pyrrolo (3,2-e)pyrazolo(1,5-a)pyrimidine derivative and medicine comprising the same
JPH0688999B2 (ja) 1988-10-13 1994-11-09 ポーラ化成工業株式会社 ピロロ〔３，２―ｅ〕ピラゾロ〔１，５―ａ〕ピリミジン誘導体およびこれを含有する医薬
JPH085790B2 (ja) * 1988-11-11 1996-01-24 杏林製薬株式会社 記憶障害改善薬
GB8901423D0 (en) 1989-01-23 1989-03-15 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
GB2229905B (en) * 1989-04-04 1993-12-08 Frederica Catharina Newman Equestrian training aid
DE3942357A1 (de) * 1989-12-21 1991-06-27 Boehringer Mannheim Gmbh 3-aminopyrazolo-heterocyclen, deren verwendung zur bestimmung von wasserstoffperoxid, wasserstoffperoxid-bildenden systemen, peroxidase, peroxidatisch wirksamen substanzen oder von elektronenreichen aromatischen verbindungen, entsprechende bestimmungsverfahren und hierfuer geeignete mittel
DE3942355A1 (de) * 1989-12-21 1991-06-27 Boehringer Mannheim Gmbh N- und o-substituierte aminophenolderivate, zwischenprodukte zu deren herstellung, deren verwendung als hydrolasesubstrate, ein entsprechendes bestimmungsverfahren und hierfuer geeignetes diagnostisches mittel
DE3942356A1 (de) * 1989-12-21 1991-06-27 Boehringer Mannheim Gmbh Verwendung von 1-arylsemicarbaziden zur stabilisierung von enzymsubstraten, entsprechende verfahren und diagnostisches mittel enthaltend einen solchen stabilisator
CA2060138A1 (en) 1991-01-29 1992-07-30 Youichi Shiokawa New use of the adenosine antagonist
JP3295149B2 (ja) 1991-12-26 2002-06-24 ポーラ化成工業株式会社 ピロロ［３，２−ｅ］ピラゾロ［１，５−ａ］ピリミジン誘導体
FR2687675B1 (fr) * 1992-01-31 1997-04-18 Roussel Uclaf Nouveaux derives bicycliques de la pyridine, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant.
JPH05271338A (ja) 1992-03-27 1993-10-19 Nippon Zeon Co Ltd 二置換ジフェニルアセチレン系重合体
EP0649425B1 (en) * 1992-06-17 1999-03-10 PHARMACIA &amp; UPJOHN COMPANY Pyridino-, pyrrolidino- and azepino-substituted oximes useful as anti-atherosclerosis and anti-hypercholesterolemic agents
JP2895961B2 (ja) 1992-12-17 1999-05-31 フアイザー・インコーポレイテツド Ｃｒｆアンタゴニストとしてのピロロピリミジン
TW336932B (en) 1992-12-17 1998-07-21 Pfizer Amino-substituted pyrazoles
KR100190730B1 (ko) 1992-12-17 1999-06-01 디. 제이. 우드, 스피겔 알렌 제이 부신피질 호르몬 유리인자(crf) 길항물질로서 치환된 피라졸
TW444018B (en) 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
PL175831B1 (pl) 1992-12-17 1999-02-26 Pfizer Pochodna pirazolu
FR2701708B1 (fr) 1993-02-19 1995-05-19 Sanofi Elf Dérivés de 2-amido-4-phénylthiazoles polysubstitués, procédé de préparation, composition pharmaceutique et utilisation de ces dérivés pour la préparation d'un médicament.
DE4311460A1 (de) * 1993-04-08 1994-10-13 Boehringer Mannheim Gmbh Verfahren zur kolorimetrischen Bestimmung eines Analyten mittels Benzylalkoholdehydrogenase und einem chromogenen Redoxindikator
WO1995010506A1 (en) 1993-10-12 1995-04-20 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
FR2714059B1 (fr) * 1993-12-21 1996-03-08 Sanofi Elf Dérivés amino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
KR100235277B1 (ko) 1994-06-16 1999-12-15 디. 제이. 우드, 스피겔 알렌 제이 피라졸로- 및 피롤로-피리딘
JP3508033B2 (ja) 1994-11-08 2004-03-22 旭電化工業株式会社 エポキシ樹脂組成物
US5955613A (en) 1995-10-13 1999-09-21 Neurogen Corporation Certain pyrrolopyridine derivatives; novel CRF1 specific ligands
DE69628804T2 (de) 1995-12-08 2003-12-18 Pfizer Substitutierte heterozyclische Derivate als CRF Antagonisten
JP3356291B2 (ja) 1996-02-07 2002-12-16 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｃｒｆレセプター拮抗薬としてのピラゾロピリミジン類
DK0882051T3 (da) 1996-02-07 2002-02-25 Janssen Pharmaceutica Nv Thiophenopyrimidiner
US6664261B2 (en) * 1996-02-07 2003-12-16 Neurocrine Biosciences, Inc. Pyrazolopyrimidines as CRF receptor antagonists
ZA973884B (en) 1996-05-23 1998-11-06 Du Pont Merck Pharma Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
US6022978A (en) 1996-06-11 2000-02-08 Pfizer Inc. Benzimidazole derivatives
US20010007867A1 (en) * 1999-12-13 2001-07-12 Yuhpyng L. Chen Substituted 6,5-hetero-bicyclic derivatives
BR9711970A (pt) 1996-08-28 1999-08-24 Pfizer Derivados 6,5-substitu¡do-heterobic¡clicos
JPH10218881A (ja) * 1997-02-03 1998-08-18 Pola Chem Ind Inc 新規なピロロピラゾロピリミジン誘導体
JP2001511813A (ja) 1997-02-18 2001-08-14 ニューロクライン バイオサイエンシーズ，インコーポレイテッド Ｃｒｆレセプターアンタゴニストおよびそれらに関連する方法
JPH1143434A (ja) 1997-05-30 1999-02-16 Pola Chem Ind Inc カリウムチャンネル開口薬
TW589309B (en) 1997-07-03 2004-06-01 Bristol Myers Squibb Pharma Co Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
EP0937081A1 (en) 1997-08-22 1999-08-25 Du Pont Pharmaceuticals Company NITROGEN SUBSTITUTED IMIDAZO 4,5-c]PYRAZOLES AS CORTICOTROPIN RELEASING HORMONE ANTAGONISTS
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
AU2298599A (en) 1998-02-04 1999-08-23 Nissan Chemical Industries Ltd. Pyridine derivatives fused with azole and herbicide
US6365589B1 (en) 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
US6271380B1 (en) 1998-12-30 2001-08-07 Dupont Pharmaceuticals Company 1H-imidazo[4,5-d]pyridazin-7-ones, 3H-imidazo-[4,5-c]pyridin-4-ones and corresponding thiones as corticotropin releasing factor (CRF) receptor ligands
AU4331500A (en) 1999-04-06 2000-10-23 Du Pont Pharmaceuticals Company Pyrazolotriazines as crf antagonists
WO2000059908A2 (en) 1999-04-06 2000-10-12 Du Pont Pharmaceuticals Company Pyrazolopyrimidines as crf antagonists
JP3795305B2 (ja) 1999-07-19 2006-07-12 田辺製薬株式会社 医薬組成物
DE50005155D1 (de) * 1999-10-08 2004-03-04 Gruenenthal Gmbh Bicyclische imidazo-3-yl-aminderivate
DE19948434A1 (de) * 1999-10-08 2001-06-07 Gruenenthal Gmbh Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine
SE9903760D0 (sv) * 1999-10-18 1999-10-18 Astra Ab New compounds
AU781227B2 (en) * 1999-10-08 2005-05-12 Grunenthal Gmbh Bicyclic imidazo-5-yl-amine derivatives
NZ518637A (en) * 1999-10-08 2004-12-24 Gruenenthal Chemie Bicyclic imidazo-3-yl amine derivatives substituted on the 6-membered ring
FR2801308B1 (fr) * 1999-11-19 2003-05-09 Oreal COMPOSITIONS DE TEINTURE DE FIBRES KERATINIQUES CONTENANT DE DES 3-AMINO PYRAZOLO-[1,(-a]-PYRIDINES, PROCEDE DE TEINTURE, NOUVELLES 3-AMINO PYRAZOLO-[1,5-a]-PYRIDINES
US7045529B2 (en) 1999-12-17 2006-05-16 Bristol-Myers Squibb Company Imidazopyrimidinyl and imidazopyri dinyl derivatives
WO2002006286A2 (en) 2000-07-14 2002-01-24 Bristol-Myers Squibb Pharma Company IMIDAZO[1,2-a]PYRAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
MY129000A (en) 2000-08-31 2007-03-30 Tanabe Seiyaku Co INHIBITORS OF a4 MEDIATED CELL ADHESION
JP3617433B2 (ja) 2000-09-05 2005-02-02 株式会社デンソー 駆動回路
RU2003126188A (ru) 2001-01-26 2005-03-27 Бристол-Маерс Сквибб Компани (Us) Имидазолильные производные как ингибиторы кортикотропин-рилизинг фактора
TWI312347B (en) * 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
JP5291854B2 (ja) * 2001-04-24 2013-09-18 マサチューセッツ インスチテュート オブ テクノロジー 炭素−ヘテロ原子間及び炭素−炭素間結合の銅を触媒とした形成
EP1389618B1 (en) * 2001-04-27 2011-06-15 Eisai R&D Management Co., Ltd. Pyrazolo 1,5-a pyridines and medicines containing the same
JP4631228B2 (ja) 2001-07-31 2011-02-16 株式会社豊田自動織機 ピストン式圧縮機における防振構造
EP1458666B1 (en) 2001-12-19 2006-08-30 Flexitral, Inc. Improved aromachemicals
MY140707A (en) 2002-02-28 2010-01-15 Mitsubishi Tanabe Pharma Corp Process for preparing a phenylalanine derivative and intermediates thereof
EP1485384A1 (en) 2002-03-13 2004-12-15 Pharmacia & Upjohn Company LLC Pyrazolo(1,5-a)pyridine derivatives as neurotransmitter modulators
EP1518187A1 (de) 2002-07-01 2005-03-30 Ognjen Amidzic Verfahren zur erstellung von daten, die für die beurteilung kognitiver oder sensomotorischer leistungsfähigkeiten oder leistungen von testpersonen verwendbar sind
JP2004053678A (ja) 2002-07-16 2004-02-19 Toyobo Co Ltd Ｉｒアブレーション用積層体
ATE426600T1 (de) * 2002-10-22 2009-04-15 Eisai R&D Man Co Ltd 7-phenylpyrazolopyridinverbindungen
US7176216B2 (en) 2002-10-22 2007-02-13 Eisai Co., Ltd. 7-phenylpyrazolopyridine compounds
WO2005063756A1 (en) * 2003-12-22 2005-07-14 Sb Pharmco Puerto Rico Inc Crf receptor antagonists and methods relating thereto
JP2008503444A (ja) 2004-02-13 2008-02-07 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド Ｃｒｆ受容体アンタゴニスト、その調製法、その医薬組成物およびその使用
JP4832743B2 (ja) 2004-03-29 2011-12-07 ケンブリッジユニバーシティテクニカルサービスリミテッド 化合物の合成方法および合成反応触媒
JP4520215B2 (ja) 2004-04-30 2010-08-04 日油株式会社 分子量が制御された置換ジフェニルアセチレン重合体の製造方法
GB0519957D0 (en) 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
US8088779B2 (en) * 2005-09-30 2012-01-03 Smithkline Beecham (Cork) Limited Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists
MY152687A (en) 2008-04-15 2014-10-31 Eisai R&D Man Co Ltd 3-phenylpyrazolo[5,1-b]thiazole compound
US7994203B2 (en) 2008-08-06 2011-08-09 Novartis Ag Organic compounds
JP2010235929A (ja) 2009-03-09 2010-10-21 Sumitomo Chemical Co Ltd 重合体
TWI358017B (en) 2009-12-17 2012-02-11 Askey Computer Corp Electronic device loading base

Also Published As

Publication number Publication date
RU2010146240A (ru) 2012-05-20
CA2721670A1 (en) 2009-10-22
CY1113484T1 (el) 2016-06-22
US8431603B2 (en) 2013-04-30
CN102007133A (zh) 2011-04-06
CN102007133B (zh) 2013-06-12
AU2009237050A1 (en) 2009-10-22
ES2396126T3 (es) 2013-02-19
HRP20121021T1 (hr) 2013-01-31
PL2266990T3 (pl) 2013-03-29
EP2266990B1 (en) 2012-09-26
HK1151797A1 (es) 2012-02-10
KR20110002007A (ko) 2011-01-06
KR101601994B1 (ko) 2016-03-17
RS52561B (en) 2013-04-30
IL208393A (en) 2013-08-29
MY152687A (en) 2014-10-31
JPWO2009128383A1 (ja) 2011-08-04
MX2010011089A (es) 2010-11-05
BRPI0911659B1 (pt) 2020-08-25
SI2266990T1 (sl) 2013-01-31
EP2266990A1 (en) 2010-12-29
JP4654325B2 (ja) 2011-03-16
NZ588376A (en) 2011-06-30
IL208393A0 (en) 2010-12-30
UA101836C2 (en) 2013-05-13
HK1150310A1 (es) 2011-11-25
RU2482120C2 (ru) 2013-05-20
AU2009237050B2 (en) 2013-04-11
BRPI0911659A2 (pt) 2015-10-13
EP2266990A4 (en) 2011-08-03
PT2266990E (pt) 2012-12-27
BRPI0911659B8 (pt) 2021-05-25
WO2009128383A1 (ja) 2009-10-22
ZA201006764B (en) 2012-03-28
AR071655A1 (es) 2010-07-07
DK2266990T3 (da) 2013-01-07
PE20091890A1 (es) 2009-12-20
CA2721670C (en) 2013-09-10
US20090259049A1 (en) 2009-10-15
TW201004964A (en) 2010-02-01

Similar Documents

Publication Publication Date Title
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
CL2012001366A1 (es) Compuestos derivados de carboxamida n-((2-morfolino-5-ariltiazol-4-il)metil), moduladores de receptores nicotinicos alfa 7; composicion farmaceutica; proceso para prepararla; combinacion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer, demencia, esquizofrenia, enfermedad de parkinson, entre otras.
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
CR20120237A (es) Derivados del ácido carbamoil-metil-amino-acético sustituido como inhibidores de nep novedosos
CL2009000896A1 (es) Compuestos derivados de 3-fenilpirazolo[5,1-b]tiazol sustituido; composicion farmaceutica; utiles en el tratamiento de la depresion, ansiedad, isquemia, apoplejia, hipertension, esquizofrenia, entre otras enfermedades.
PE20170666A1 (es) 2-(morfolin-4-il)-1,7-naftiridinas
CO6470846A2 (es) Derivados aminobut´ricos sustituidos como inhibidores de neprilisina
UY30966A1 (es) Nuevos compuestos de adenina, sales farmaccuticamente aceptables, composiciones contenicndolos y aplicaciones
CR10148A (es) Derivados de las benzamidas y heteroarenos
PE20141682A1 (es) Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio
CO6541656A2 (es) 2-amino-5.5- difluor-5.6-dihidro-4h-oxazinas como inhibidores de bace1 y/o bace 2
CU20110217A7 (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
GT200600081A (es) Derivados de acetilenno
ECSP055676A (es) Piperazinas heterocíclicas sustituidas para el tratamiento de la esquizofrenia
UY31127A1 (es) Ligandos de oxiadazol del receptor metabotropico para el glutamato y su utilizacion como potenciadores - 841
UY32547A (es) Piperidinas sustituidas como antagonistas de ccr3
GT200800242A (es) Derivados biciclicos como inhibidores de cetp
UY30316A1 (es) Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones
UY29198A1 (es) Derivados sustituidos de quinazolinona y derivados sustituidos de quinazolina-2, 4-diona, composiciones conteniéndolos, procedimientos de preparación y aplicaciones
CL2007003289A1 (es) Compuestos derivados de biciclocarboxiamida; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades provocadas por la hiperactivacion del receptor vc1 como dolor, enfermedad de vejiga, inflam
DE602008001983D1 (de) Pyrrolidinderivate als doppelte nk1/nk3-rezeptorenantagonisten
CL2011000544A1 (es) Compuestos derivados de benzamida n sustituida por heterociclo, ligandos de los receptores cannabinoides; composicion farmaceutica; y su uso para tratar el dolor, entre otras enfermedades.
CL2013000488A1 (es) Co-cristales de compuestos derivados de (2r)-5-oxo-1-(bencilpiperidin-4-il)-n-(piridin-2-il)pirrolidin-2-carboxamida y un agente de formacion de co-cristales; sales de los compuestos; compuestos intermediarios; composicion farmaceutica; y su uso para el tratamiento de enfermedades inflamatorias e infecciosas.
ECSP088967A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
CL2008001670A1 (es) Compuestos derivados de piperidina o piperazina, inhibidores de dgat1; composicion farmaceutica; combinacion farmaceutica; y uso para la prevencion o tratamiento de enfermedades tales como obesidad, hipercolesterolemia, dislipidemia, entre otras.